Furthermore, among patients with actionable alterations in RAS/RAF pathway, one-third of the right-sided tumours, and one-fifth of the left-sided tumours could benefit from combined therapies that simultaneously target RAS/RAF and PI3K pathways. This evidence concerns the gene PIK3CA and neoplasm.